Be The Match BioTherapies

Labiotech.eu | January 28, 2020

A Swiss research group has developed tiny plastic particles that could carry gene therapies to the center of the cell with less risk of getting attacked by the immune system than conventional gene therapies. The majority of gene therapies in use today are delivered to the DNA of target cells using viral vectors. While efficient at their job, viral vectors can risk triggering the immune system to destroy them. This can lead to the therapy becoming ineffective....

FierceBiotech | January 27, 2020

Johnson & Johnson is joining the growing ranks of biopharmas, including the likes of Moderna and Gilead Sciences, in trying to create a speedy vaccine for the coronavirus out of China. Over the weekend, we learned of a wider range and more deaths as the new virus, which appears to have come out of Wuhan, China, is doing what these diseases do best: spread. The causes of death have so far been reported as pneumonia, with other reports suggesting most of these have come from those with underly...

Questex LLC | January 22, 2019

Gamida Cell is teaming up with Be The Match BioTherapies, a service-focused subsidiary of the National Marrow Donor Program, to help support the late-phase development of its cell therapy that aims to offer an alternative source of universal bone marrow transplant material for patients with blood cancers. The collaboration plans to employ the Be The Match Registry, which includes more than 20 million potential donors, as well as provide case management, logistics, and other services for an ongoi...

FierceBiotech | January 21, 2020

LabCorp has unveiled a new suite of cell and gene therapy development offerings from Covance as it looks to get in on this burgeoning new trend. “These solutions are designed to reduce time and risk for sponsors at each phase and across the full continuum of their therapy development needs in one of the industry’s fastest-growing segments,” Covance, the CRO unit of diagnostics giant LabCorp, said in a statement. This follows the first CAR-T cell therapy approvals from Novartis ...